How have CRMD shares performed this year?

CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have increased by 53.2% and is now trading at $5.76. View the best growth stocks for 2024 here .

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business earned $0.81 million during the quarter, compared to analysts' expectations of $0.75 million.

When did CorMedix's stock split?

CorMedix's stock reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Who are CorMedix's major shareholders?

CorMedix's top institutional investors include Renaissance Technologies LLC (0.29%), Bank of New York Mellon Corp (0.29%), Marshall Wace LLP (0.28%) and Commonwealth Equity Services LLC (0.17%). Insiders that own company stock include Myron Kaplan and Matthew T David. View institutional ownership trends .

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Amarin (AMRN) , NVIDIA (NVDA) , AcelRx Pharmaceuticals (ACRX) , Gigamon (GIMO) , Conatus Pharmaceuticals (CNAT) , Nabriva Therapeutics (NBRV) and QUALCOMM (QCOM) .

NASDAQ:CRMD

CorMedix (CRMD) Stock Price, News & Analysis

$5.76

+0.06 (+1.05%)

(As of 09/6/2024 ET)

Compare

Today's Range: $5.31
▼
$5.81
50-Day Range: $3.64
▼
$6.27
52-Week Range: $2.57
▼
$7.00

Volume: 832,998 shs
Average Volume: 569,609 shs
Market Capitalization: $316.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.60

Get CorMedix alerts:

CorMedix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 118.8% Upside
$12.60 Price Target
Short Interest: Bearish
18.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.58) to $0.17 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.01 out of 5 stars

Medical Sector

769th out of 910 stocks

Pharmaceutical Preparations Industry

359th out of 426 stocks

3.5

Analyst's Opinion

Consensus Rating
CorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CorMedix has only been the subject of 4 research reports in the past 90 days.
Read more about CorMedix's stock forecast and price target.

0.0

Short Interest

Percentage of Shares Shorted
18.78% of the outstanding shares of CorMedix have been sold short.
Short Interest Ratio / Days to Cover
CorMedix has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.
Change versus previous month
Short interest in CorMedix has recently increased by 1.18%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
CorMedix does not currently pay a dividend.
Dividend Growth
CorMedix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRMD.

3.2

News and Social Media Coverage

News Sentiment
CorMedix has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
Search Interest
15 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CorMedix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.60% of the stock of CorMedix is held by insiders.
Percentage Held by Institutions
Only 34.18% of the stock of CorMedix is held by institutions.
Read more about CorMedix's insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CorMedix are expected to grow in the coming year, from ($0.58) to $0.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CorMedix is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CorMedix is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CorMedix has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about CorMedix's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

Who are Nvidia’s New Silent Partners?

Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.

I call these Nvidia’s “Silent Partners.”

About CorMedix Stock (NASDAQ:CRMD)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CRMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRMD Stock News Headlines

August 28, 2024 | uk.finance.yahoo.com

Cormedix Inc (19KA.SG)

August 28, 2024 | americanbankingnews.com

Rodman & Renshaw Initiates Coverage on CorMedix (NASDAQ:CRMD)

September 7, 2024 | Porter & Company (Ad)

Why billionaires are wiring money to abandoned towns

A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.

August 27, 2024 | msn.com

Rodman & Renshaw Initiates Coverage of CorMedix (CRMD) with Buy Recommendation

August 19, 2024 | finance.yahoo.com

CVAC Sep 2024 2.000 call (CVAC240920C00002000)

August 18, 2024 | ca.finance.yahoo.com

CRMD Sep 2024 8.000 put